Conceptual changes in ameloblastoma: Suggested re-classification of a "veteran" tumor.

Autor: Zlotogorski-Hurvitz A; Department of Oral Pathology, Oral Medicine and Maxillofacial Imaging, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Oral & Maxillofacial Surgery, Rabin Medical Center, Petah Tikva, Israel., Soluk Tekkeşin M; Department of Tumour Pathology, Institute of Oncology, Istanbul University, Istanbul, Turkey., Passador-Santos F; Department of Oral Pathology, São Leopoldo Mandic Research Center, Campinas, Brazil., Martins Montalli VA; Department of Oral Pathology, São Leopoldo Mandic Research Center, Campinas, Brazil., Salo T; Translational Immunology Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.; Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.; Cancer Research and Translational Medicine Research Unit, Faculty of Medicine, University of Oulu, Oulu, Finland.; Department of Pathology, HUSLAB, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland., Mauramo M; Department of Pathology, HUSLAB, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.; University Central Hospital, Helsinki, Finland., Kats L; Department of Oral Pathology, Oral Medicine and Maxillofacial Imaging, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel., Buchner A; Department of Oral Pathology, Oral Medicine and Maxillofacial Imaging, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel., Vered M; Department of Oral Pathology, Oral Medicine and Maxillofacial Imaging, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.; Institute of Pathology, Sheba Medical Center, Ramat Gan, Israel.
Jazyk: angličtina
Zdroj: Oral diseases [Oral Dis] 2022 Apr; Vol. 28 (3), pp. 703-710. Date of Electronic Publication: 2021 Jan 21.
DOI: 10.1111/odi.13770
Abstrakt: Objectives: The merging of ameloblastoma (AM) with mural unicystic ameloblastoma (UAM-M) was suggested by the 2017 WHO based on similar treatment needs. In an international multicenter study, we investigated the characteristics of their merged product (merged-AM) and raised the possibility of unifying AM and UAM (total-AM).
Materials and Methods: AM and UAM (luminal/intraluminal/mural), separate and combined, were analyzed for demographic/clinical/radiological features. ANOVA and chi-square tests were followed by univariate and multivariate analyses, and significance was set at p < .05.
Results: The patients' mean age was 39.6 ± 20.3 years in merged-AM (147 AM, 76 UAM-M), 45.1 ± 19.4 years in AM (p = .009). Merged-AM comprised 51.3% multilocular/48.7% unilocular tumors, AM comprised 72.5%/27.5%, respectively (p < .001). Merged-AM was associated with impacted teeth in 30.8%, AM in 18% (p = .023). The probability of merged-AM for multilocularity increased by 2.4% per year of age (95%CI 0.6-4.2, p = .009). Association with impacted teeth decreased by 7.9% per year of age (95%CI 1.9-14.39, p = .009). Merged-AM did not differ from total-AM (p > .05).
Conclusions: Merged-AM partially differed from AM, but differences appeared to diminish in an age/time-wise manner. Merged-AM and total-AM were nearly indistinguishable. Therefore, AM and UAM may be considered a continuous spectrum of one type of tumor, further necessitating revision of the treatment approaches.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: